Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOT-MS discontinuation trial in stable relapsing-onset multiple sclerosis
NL-OMON21462Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of interferon beta-1a, glatiramer acetate, dimethyl fumarate and teriflunomide in multiple sclerosis (MS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Return of inflammatory disease activity at 2 years, Clinically confirmed relapse and 1 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
interferon beta-1aglatiramer acetatedimethyl fumarateteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON21462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21462.